The SCOUT Study - Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation
Sponsor: |
Mitralign Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ1711 |
U.S. Govt. ID: |
NCT02574650 |
Contact: |
Lauren Privitera: 212-342-3488 / lp2183@cumc.columbia.edu |
This study is for patients who suffer from a leakage of blood within on of the valves of the heart. The leakage of blood is also called regurgitation. The valve that is leaking is called the tricuspid valve and it is located within the right side of the heart. This condition is referred to as functional tricuspid regurgitation (FTR). The treatment of FTR depends on how severe it is and the general condition of the heart. Some types of tricuspid regurgitation may be treated with different categories of medication while others may require openheart surgery.The purpose of this study is to see the effectiveness of a new tricuspid valve repair device which will be inserted in the blood vessels through the neck to deliver threads to allow doctors to tighten the valve so it doesn't leak as much. Implanting this device does not require open-heart surgery.
This study is closed
Investigator
Rebecca Hahn, MD
Do you have chronic functional tricuspid regurgitation (FTR)? |
Yes |
No |
Do you have a diuretic regimen ? |
Yes |
No |